| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Tarlatamab (anti-DLL3&CD3)
CAS:2307488-83-9
Package:100μg;1mg Remarks:K30794
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Tarlatamab
CAS:2307488-83-9
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Tarlatamab
CAS:2307488-83-9
Purity:>95% Package:100ug;200ug;1mg
|
Tarlatamab manufacturers
- Tarlatamab
-
- $619.00
-
2026-08-14
- CAS:2307488-83-9
- Purity: 95.00%
- Supply Ability: 10g
|
| | Tarlatamab Basic information |
| Product Name: | Tarlatamab | | Synonyms: | Tarlatamab;Research Grade Tarlatamab (DHK06402);Research Grade Tarlatamab;Tarlatamab (anti-DLL3&CD3) | | CAS: | 2307488-83-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tarlatamab Structure]() |
| | Tarlatamab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Tarlatamab Usage And Synthesis |
| Uses | Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research[1]. | | in vivo | Tarlatamab (AMG-757; 3 mg/kg; IP; once weekly for 3 weeks) drives tumor regression in mouse models of SCLC[1].
Tarlatamab (IP; 12 μg/kg; single dose) has a mean half-life of 234 hours (9.8 days), a mean clearance of 0.487 mL/hour/kg and a steady-state volume of distribution of 146 mL/kg in nonhuman primates (NHPs)[1].
| Animal Model: | Female NOD.Cg-PrkdcscidIl2rgtm1Sug/JicTac (NOG) mice with patient-derived SCLC tumor fragments (LXFS 1129 and LXFS 538)[1] | | Dosage: | 3 mg/kg | | Administration: | IP; once weekly for 3 weeks | | Result: | Led to 83% tumor regression and an overall significant reduction in tumor volume compared with that in mice which received a control HLE BiTE molecule in the LXFS 1129 model.
Induced 98% tumor regression in the LXFS 538 model.
|
| | References | [1] Michael J Giffin, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021 Mar 1;27(5):1526-1537. DOI:10.1158/1078-0432.CCR-20-2845 |
| | Tarlatamab Preparation Products And Raw materials |
|